<DOC>
	<DOCNO>NCT00372424</DOCNO>
	<brief_summary>This exploratory trial evaluate tolerability preliminary anti-tumor activity SU011248 combine docetaxel trastuzumab patient locally recurrent metastatic breast cancer over-expressing Her-2 , receive chemotherapy treatment advance disease setting .</brief_summary>
	<brief_title>Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Breast cancer evidence unresectable , locally recurrent , metastatic disease . Tumors overexpressing Her2 Candidate treatment docetaxel/trastuzumab Histology inflammatory carcinoma AST and/or ALT &gt; 1.5 x ULN concomitant ALP &gt; 2.5 x ULN</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Breast cancer over-expressing HER2 . First-line treatment sunitinib/docetaxel/trastuzumab .</keyword>
</DOC>